Lorcaserin is a 5-HT2CR agonist approved for weight management, but it was withdrawn in 2020 due to a numerical imbalance in the cancers occurring in an over 12,000-participant clinical trial (118)
These milestones highlight the growing regulatory and clinical momentum supporting expanded uses Ongoing trials are also exploring the impact of GLP-1 agonists on cardiovascular outcomes, liver health, and even neurodegenerative diseases, reinforcing their value in treating systemic metabolic disorders
The recent position statement by the ADA advocating the use of both SGLT2i and GLP-1 RAs is encouraging, indicating that CKD in T2DM is under the spotlight
In the body we create miniscule amounts of L-carnitine and certain health conditions can reduce production of this substance even further
If nausea persists or worsens, consult a healthcare provider promptly
It's important to note that while semaglutide can be a powerful tool in the fight against obesity, it is not a magic solution